Literature DB >> 25556181

Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences.

Iulia Potorac1, Patrick Petrossians1, Adrian F Daly1, Franck Schillo1, Claude Ben Slama1, Sonia Nagi1, Mouna Sahnoun1, Thierry Brue1, Nadine Girard1, Philippe Chanson1, Ghaidaa Nasser1, Philippe Caron1, Fabrice Bonneville1, Gérald Raverot1, Véronique Lapras1, François Cotton1, Brigitte Delemer1, Brigitte Higel1, Anne Boulin1, Stéphan Gaillard1, Florina Luca1, Bernard Goichot1, Jean-Louis Dietemann1, Albert Beckers2, Jean-François Bonneville1.   

Abstract

Responses of GH-secreting adenomas to multimodal management of acromegaly vary widely between patients. Understanding the behavioral patterns of GH-secreting adenomas by identifying factors predictive of their evolution is a research priority. The aim of this study was to clarify the relationship between the T2-weighted adenoma signal on diagnostic magnetic resonance imaging (MRI) in acromegaly and clinical and biological features at diagnosis. An international, multicenter, retrospective analysis was performed using a large population of 297 acromegalic patients recently diagnosed with available diagnostic MRI evaluations. The study was conducted at ten endocrine tertiary referral centers. Clinical and biochemical characteristics, and MRI signal findings were evaluated. T2-hypointense adenomas represented 52.9% of the series, were smaller than their T2-hyperintense and isointense counterparts (P<0.0001), were associated with higher IGF1 levels (P=0.0001), invaded the cavernous sinus less frequently (P=0.0002), and rarely caused optic chiasm compression (P<0.0001). Acromegalic men tended to be younger at diagnosis than women (P=0.067) and presented higher IGF1 values (P=0.01). Although in total, adenomas had a predominantly inferior extension in 45.8% of cases, in men this was more frequent (P<0.0001), whereas in women optic chiasm compression of macroadenomas occurred more often (P=0.0067). Most adenomas (45.1%) measured between 11 and 20 mm in maximal diameter and bigger adenomas were diagnosed at younger ages (P=0.0001). The T2-weighted signal differentiates GH-secreting adenomas into subgroups with particular behaviors. This raises the question of whether the T2-weighted signal could represent a factor in the classification of acromegalic patients in future studies.
© 2015 Society for Endocrinology.

Entities:  

Keywords:  MRI; T2-weighted signal; acromegaly; pituitary adenoma

Mesh:

Substances:

Year:  2015        PMID: 25556181     DOI: 10.1530/ERC-14-0305

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  29 in total

1.  MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly.

Authors:  Ansgar Heck; Kyrre E Emblem; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2015-11-28       Impact factor: 3.633

2.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

Review 3.  T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective.

Authors:  Iulia Potorac; Albert Beckers; Jean-François Bonneville
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.

Authors:  Liang Lv; Yong Jiang; Senlin Yin; Yu Hu; Cheng Chen; Weichao Ma; Shu Jiang; Peizhi Zhou
Journal:  Endocrine       Date:  2019-07-31       Impact factor: 3.633

Review 5.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

6.  Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.

Authors:  Ansgar Heck; Kyrre E Emblem; Olivera Casar-Borota; Jens Bollerslev; Geir Ringstad
Journal:  Endocrine       Date:  2015-10-16       Impact factor: 3.633

7.  T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.

Authors:  M C Burlacu; D Maiter; T Duprez; E Delgrange
Journal:  Endocrine       Date:  2018-09-28       Impact factor: 3.633

8.  Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly.

Authors:  Ming Shen; Qilin Zhang; Wenjuan Liu; Meng Wang; Jingjing Zhu; Zengyi Ma; Wenqiang He; Shiqi Li; Xuefei Shou; Yiming Li; Zhaoyun Zhang; Hongying Ye; Min He; Bin Lu; Zhenwei Yao; Yun Lu; Nidan Qiao; Zhao Ye; Yichao Zhang; Yeping Yang; Yao Zhao; Yongfei Wang
Journal:  Neuroradiology       Date:  2016-08-11       Impact factor: 2.804

9.  Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.

Authors:  Sema Ciftci Dogansen; Gulsah Yenidunya Yalin; Seher Tanrikulu; Sakin Tekin; Nihan Nizam; Bilge Bilgic; Serra Sencer; Sema Yarman
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

10.  MRI criteria of subtypes of adenomas and epithelial cysts of the pituitary gland.

Authors:  Stefanie Bette; Vicki M Butenschön; Benedikt Wiestler; Alexander von Werder; Roland M Schmid; Jens Lehmberg; Claus Zimmer; Bernhard Meyer; Jan S Kirschke; Jens Gempt
Journal:  Neurosurg Rev       Date:  2018-11-13       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.